Abstract 1710P
Background
Although eligibility criteria are an essential component of clinical trial design, overly restrictive criteria contribute to low accrual and poor generalizability of study results. To make trials more inclusive, there has been an increasing interest in broadening eligibility criteria, but how this affects patient safety remains unclear. In the Drug Rediscovery Protocol (DRUP, NCT02925234), protocol exceptions that were granted by the study team, taking into account the balance of potential benefits and risks, were analyzed. Here we describe the impact of these protocol waivers on patient safety and treatment efficacy.
Methods
DRUP is a Dutch multicentred, non-randomized, pan-cancer platform trial in which treatment-refractory patients are treated with targeted- and immunotherapies outside their registered indications, based on their tumor molecular profile. We collected data of all included patients for whom a waiver was granted and analyzed them in terms of treatment safety and efficacy. Also, safety and efficacy outcomes of these patients were compared to those of patients that did not need a waiver to participate.
Results
Between September 1, 2016, and September 1, 2021, 1019 patients were included in DRUP. In total, 88 protocol waivers were granted for 82 patients (8%). Most waivers were granted for general- or drug-related eligibility criteria (44%). For 32 of 82 patients that received a waiver (39%), 49 SAEs regardless of relationship to study treatment, were reported. For the included patients without a waiver (n=937), 666 SAEs were reported in 385 patients (41%, p = 0.81). The clinical benefit rate (CBR; either objective response or stable disease (SD) ≥ 16 weeks) of patients for whom a waiver was granted was 40% (14 patients (17%) with a partial response and 19 (23%) with SD ≥ 16 weeks), compared to a CBR of 33% in the non-waiver population (p = 0.43).
Conclusions
Safety and clinical benefit were preserved in patients for whom a waiver was granted in DRUP. Our data advocate omittance of ‘old’ unnecessarily strict safety criteria when setting up molecularly driven trials and support a more personalized approach in assessing eligibility criteria, especially in trials with therapeutic intent for patients without other treatment options.
Clinical trial identification
NCT02925234.
Editorial acknowledgement
Legal entity responsible for the study
The Netherlands Cancer Institute.
Funding
Stelvio for Life Foundation: funding; Dutch Cancer Society (KWF): funding; Hartwig Medical Foundation (HMF): genome sequencing; Pharmaceutical partners (Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Janssen, Lilly, Merck, Novartis, Pfizer, Roche): funding and study drugs.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1727P - Barriers and facilitators of physician involvement in clinical oncology database management in Ukraine
Presenter: Inesa Huivaniuk
Session: Poster session 23
1728P - Implementation of a comprehensive oncology unit: Needs detected in cancer survivors during follow-up
Presenter: Francisco J Jimenez-ruiz
Session: Poster session 23
1729P - Targeted interventions in registration and reporting of multidisciplinary team meetings (MDT) in oncology help to improve tumor board decisions
Presenter: Lars Galonska
Session: Poster session 23
1730P - Dealing with digital paralysis: Surviving a cyberattack in a cancer centre
Presenter: Rachel J. Keogh
Session: Poster session 23
1731P - Providing access to anticancer drugs within an armed conflict: The experience of Mission Kharkiv (MK) and Medecins Sans Frontieres (MSF) in Ukraine
Presenter: Stanislav Polozov
Session: Poster session 23
1732P - War and the fragility of anticancer drug supply networks in Ukraine
Presenter: Olha Kostenchak-Svystak
Session: Poster session 23
1733P - Two wars at time: Fight against cancer during war time - experience of Ukraine
Presenter: Veronika Patsko
Session: Poster session 23
1734P - Early impact of a personalized lung cancer interception program for heavy smokers
Presenter: Pamela Abdayem
Session: Poster session 23
1735P - Impact of revised US Preventive Services Task Force (USPSTF) 2021 lung cancer screening guideline on long-term cancer survivors in the United States
Presenter: Qian Wang
Session: Poster session 23
1736P - Young adult lung cancer demands more attention in a low-resource area: Bangladesh perspective
Presenter: Muhammad Rafiqul Islam
Session: Poster session 23